TAK-935-18-001
Recruitment Complete
A Study of Soticlestat in Adults and Children With Rare Epilepsies
About this clinical trial
The main aim is to assess the long-term safety and tolerability of soticlestat when used along with other anti-seizure treatment. Participants will receive soticlestat twice a day. Participants will visit the study clinic every 2-6 months throughout the study. Study treatments may continue as long as the participant is receiving benefit from it.
US
CN
IL
5+
Interventional Phase 2 clinical trial.
At a glance
What medical conditions were being studied?
Dravet Syndrome (DS)
Lennox-Gastaut Syndrome (LGS)
Epilepsy
What was the clinical trial testing?
Soticlestat
How many participants were enrolled?
156
Were placebos part of the clinical trial?
No
When was the clinical trial conducted?
Jul 2018 - May 2026
How long was participation in the clinical trial?
Participants will be in the study for up to approximately 6 years.
Key requirements
Sexes
All
Age
2+ Years
Healthy volunteers?
No
Entry criteria
Both male and female can take part.
Must be diagnosed with epilepsy.
Must be at least 2 years old or older.
Must have been treated with soticlestat in a previous clinical study.
Additional entry criteria will be discussed with the study doctor.